JP2001515708A5 - - Google Patents

Download PDF

Info

Publication number
JP2001515708A5
JP2001515708A5 JP2000510463A JP2000510463A JP2001515708A5 JP 2001515708 A5 JP2001515708 A5 JP 2001515708A5 JP 2000510463 A JP2000510463 A JP 2000510463A JP 2000510463 A JP2000510463 A JP 2000510463A JP 2001515708 A5 JP2001515708 A5 JP 2001515708A5
Authority
JP
Japan
Prior art keywords
heavy chain
antibody
humanized
sasnryt
ngfwi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2000510463A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001515708A (ja
Filing date
Publication date
Priority claimed from US08/925,339 external-priority patent/US6440418B1/en
Application filed filed Critical
Publication of JP2001515708A publication Critical patent/JP2001515708A/ja
Publication of JP2001515708A5 publication Critical patent/JP2001515708A5/ja
Abandoned legal-status Critical Current

Links

JP2000510463A 1997-09-08 1998-09-08 ヒトgp39に対するヒト化抗体、当該抗体を含む組成物およびその治療的使用 Abandoned JP2001515708A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/925,339 US6440418B1 (en) 1995-11-07 1997-09-08 Methods of treating autoimmune diseases with gp39-specific antibodies
US08/925,339 1997-09-08
PCT/US1998/018163 WO1999012566A1 (en) 1997-09-08 1998-09-08 HUMANIZED ANTIBODIES TO HUMAN gp39, COMPOSITIONS CONTAINING AND THERAPEUTIC USE THEREOF

Publications (2)

Publication Number Publication Date
JP2001515708A JP2001515708A (ja) 2001-09-25
JP2001515708A5 true JP2001515708A5 (cg-RX-API-DMAC10.html) 2006-07-06

Family

ID=25451580

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000510463A Abandoned JP2001515708A (ja) 1997-09-08 1998-09-08 ヒトgp39に対するヒト化抗体、当該抗体を含む組成物およびその治療的使用

Country Status (11)

Country Link
US (3) US6440418B1 (cg-RX-API-DMAC10.html)
EP (1) EP1011725A4 (cg-RX-API-DMAC10.html)
JP (1) JP2001515708A (cg-RX-API-DMAC10.html)
KR (1) KR100574591B1 (cg-RX-API-DMAC10.html)
CN (1) CN1278736A (cg-RX-API-DMAC10.html)
AU (1) AU740981B2 (cg-RX-API-DMAC10.html)
CA (1) CA2302752A1 (cg-RX-API-DMAC10.html)
IL (1) IL134888A0 (cg-RX-API-DMAC10.html)
NO (1) NO20001104L (cg-RX-API-DMAC10.html)
RU (1) RU2207878C2 (cg-RX-API-DMAC10.html)
WO (1) WO1999012566A1 (cg-RX-API-DMAC10.html)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6440418B1 (en) * 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
CN1572325A (zh) * 1997-01-10 2005-02-02 拜奥根Idec马萨诸塞公司 用抗cd40l化合物治疗狼疮性肾炎
CA2223225A1 (en) * 1997-11-28 1999-05-28 Canadian Red Cross Society Method for inhibiting in vivo immune response
US7163686B1 (en) * 1999-05-15 2007-01-16 The Regents Of The University Of California Protein A based binding domains with desirable activities
EP1101495A4 (en) * 1999-06-01 2003-05-07 Eisai Co Ltd PREVENTIVE AGENTS AGAINST IDIOPATHIC THROMOBOCYTOPENIC PURPURA
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
EP1839674A1 (en) * 1999-10-04 2007-10-03 Novartis Vaccines and Diagnostics, Inc. CD40 antagonist for treating psoriasis
DE60035057T2 (de) * 1999-10-04 2008-01-31 Novartis Vaccines and Diagnostics, Inc., Emeryville CD40 Antagonist zur Behandlung von Psoriasis
EP1223981B1 (en) * 1999-10-22 2008-01-16 Biogen Idec MA Inc. Use of a cd40:cd154 binding interruptor to treat immunological complications of the eye
GB0006398D0 (en) * 2000-03-16 2000-05-03 Novartis Ag Organic compounds
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
EP1284747A2 (en) 2000-05-12 2003-02-26 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for achieving immune suppression
AU7522401A (en) * 2000-06-06 2001-12-17 Idec Pharma Corp Non-agonistic antibodies to human gp39, compositions containing, and therapeuticuse thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
WO2003086463A1 (en) * 2002-04-03 2003-10-23 Keio University Remedies for pemphigus containing cd40l antagonist as the active ingredient
US9259459B2 (en) * 2003-01-31 2016-02-16 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
WO2004074432A2 (en) * 2003-01-31 2004-09-02 Celldex Therapeutics, Inc. Antibody vaccine conjugates and uses therefor
RU2240134C1 (ru) * 2003-02-17 2004-11-20 Козлов Владимир Александрович Способ лечения больных сахарным диабетом
US20050079234A1 (en) * 2003-08-27 2005-04-14 Chiang Yang Chi Compositions comprising herbs and method for immunomodulation
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
US20080279850A1 (en) * 2005-07-25 2008-11-13 Trubion Pharmaceuticals, Inc. B-Cell Reduction Using CD37-Specific and CD20-Specific Binding Molecules
AU2006272555B2 (en) 2005-07-25 2012-03-08 Aptevo Research And Development Llc B-cell reduction using CD37-specific and CD20-specific binding molecules
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
US8236318B2 (en) 2007-11-07 2012-08-07 Celldex Therapeutics Inc. Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
NZ603059A (en) 2008-04-11 2014-07-25 Emergent Product Dev Seattle Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
WO2010003193A1 (en) * 2008-07-11 2010-01-14 Phylogica Limited Peptide inhibitors of cd40l signaling and uses therefor
BRPI1009455A2 (pt) 2009-03-10 2016-03-01 Baylor Res Inst anticorpos anti-c40 e usos dos mesmos
BRPI1009454A2 (pt) 2009-03-10 2019-09-24 Baylor Res Institute vacinas contra o câncer direcionadas a células apresentadoras de antígenos
US20130028897A1 (en) * 2009-04-27 2013-01-31 Ali Naji Methods for reducing the level of alloantibodies in a subject
RU2439712C1 (ru) * 2010-07-21 2012-01-10 Сергей Валентинович Логвинов Способ моделирования аутоиммунного оофорита
CN107881196A (zh) * 2011-12-22 2018-04-06 弗·哈夫曼-拉罗切有限公司 表达载体组织、新的生产用细胞产生方法及其在重组产生多肽中的用途
WO2014153056A2 (en) 2013-03-14 2014-09-25 Parkash Gill Cancer treatment using antibodies that bing cell surface grp78
WO2015106281A1 (en) 2014-01-13 2015-07-16 Baylor Research Institute Novel vaccines against hpv and hpv-related diseases
SG10201913431QA (en) 2015-07-14 2020-03-30 Immunext Inc Anti-cd154 antibody having improved binding, functional and safety characteristics and use in human immunotherapy
MY188405A (en) 2015-08-05 2021-12-08 Janssen Biotech Inc Anti-cd154 antibodies and methods of using them
HK1251480A1 (zh) 2015-09-21 2019-02-01 Aptevo Research And Development Llc Cd3结合多肽
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
US20230151102A1 (en) 2020-01-13 2023-05-18 Aptevo Research And Development Llc Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components
CN115279406A (zh) 2020-01-13 2022-11-01 阿帕特夫研究和发展有限公司 蛋白质治疗剂的调配物
US20240262920A1 (en) 2021-05-21 2024-08-08 Aptevo Research And Development Llc Dosing regimens for protein therapeutics

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5092585A (en) 1987-06-11 1992-03-03 Jones Arthur A Apparatus for testing and/or exercising the cervical muscles of the human body
US4978745A (en) 1987-11-23 1990-12-18 Centocor, Inc. Immunoreactive heterochain antibodies
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
DK0897983T3 (da) 1991-10-25 2003-08-11 Immunex Corp Antistoffer mod CD40-L
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
CA2089229C (en) 1992-02-14 2010-04-13 Alejandro A. Aruffo Cd40cr receptor and ligands therefor
WO1994004570A1 (en) 1992-08-21 1994-03-03 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
US5540926A (en) 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
JP2840131B2 (ja) 1993-09-02 1998-12-24 トラスティーズ・オブ・ダートマス・カレッジ 液性免疫の持続性抑制方法
CN1127351C (zh) * 1993-09-02 2003-11-12 达特茅斯学院理事 诱导抗原特异性t细胞耐受的方法
US5683693A (en) 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
GB9507719D0 (en) * 1995-04-13 1995-05-31 Boc Group Plc Machining of materials
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US6440418B1 (en) 1995-11-07 2002-08-27 Idec Pharmaceuticals Corporation Methods of treating autoimmune diseases with gp39-specific antibodies
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
WO1998008541A1 (en) 1996-08-30 1998-03-05 Genzyme Corporation Inhibition of primary and/or secondary immune response to repeat adenoviral vector administration using cd40l specific antibodies

Similar Documents

Publication Publication Date Title
RU2207878C2 (ru) "очеловеченные" антитела против gp39 человека, композиции, содержащие эти антитела, и их терапевтическое использование
ES2384168T3 (es) Procedimientos de tratamiento usando anticuerpos CTLA-4
EP2447281B1 (en) Novel anti-PLGF antibody
JP2022031638A (ja) 放射線療法と併用されるpd-1およびpd-l1に対する拮抗薬を用いたがんの治療法
CN1202864C (zh) Cd40:cd154结合阻断物在制备预防逆适应性免疫应答,特别是移植物排斥反应的药物中的用途
UA125382C2 (uk) Антитіла проти людського vista та їх застосування
WO1994008619A1 (en) Treatment of autoimmune and inflammatory disorders
RU2000109255A (ru) "очеловеченные" антитела против gp39 человека, композиции, содержащие эти антитела, и их терапевтическое использование
RU2009149294A (ru) Антиген-связывающие белки, нацеленные на orf0657n s.aureus
JP2026050362A (ja) Car-t細胞のインサイチュ動員、リプログラミングおよび放出
MXPA06008746A (es) Metodos y composiciones para tratamiento de tumores y enfermedad metastatica.
CN104105505A (zh) 用于治疗类风湿性关节炎的组合物及其使用方法
CN114729031A (zh) 抗溶瘤病毒抗原抗体及其使用方法
JP2020510039A5 (cg-RX-API-DMAC10.html)
US20220259313A1 (en) Administration of a pd-1 inhibitor for for treating skin cancer
JP2016172759A (ja) 抗cd3免疫分子療法により肝炎を治療する方法および組成物
JP2021534195A5 (cg-RX-API-DMAC10.html)
CN113038939A (zh) 损害内施用pd-1抑制剂用于治疗皮肤癌
CN112996909A (zh) 表达pd-1结合蛋白的溶瘤病毒及其应用
US20060153805A1 (en) Viral vectors and the use of the same for gene therapy
JP6890340B6 (ja) グルカゴン受容体アンタゴニスト抗体を用いた心不全の治療法
CN119677533A (zh) 用于治疗癌症的检查点抑制剂与溶瘤病毒的组合
CN118871127A (zh) 用于治疗头颈癌的三重组合药物给药疗法
ES2326978T3 (es) Procedimiento de tratamiento del carcinoma hepatocelular.
JP2003089656A (ja) 移植による免疫反応抑制剤